Maxcyte, Inc. (MXCT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Of the 6 companies Maxcyte, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 8731, Services-Commercial Physical & Biological Research, from each company's own filings. Largest first.
Maxcyte, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Commercial Physical & Biological Research
High 1.20 at 9:30 am ET, low 1.16 at 2:00 pm ET.
the bull case· 2
5
disclosed supplier and customer ties in SEC filings
sec filingsedgar20
managers whose positions together make up four fifths of the reported value
13fJun 30 '26the bear case· 3
−9.13%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '264 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '268 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
tall tick = annual report · 1 on record
122 managers report a position worth $78.2M between them, and 20 of them hold 80% of it.
MXCT (Maxcyte, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.